Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Alan R. Shuldiner"'
Autor:
Craig R. Lee, Jasmine A. Luzum, Katrin Sangkuhl, Roseann S. Gammal, Marc S. Sabatine, Charles Michael Stein, David F. Kisor, Nita A. Limdi, Yee Ming Lee, Stuart A. Scott, Jean‐Sébastien Hulot, Dan M. Roden, Andrea Gaedigk, Kelly E. Caudle, Teri E. Klein, Julie A. Johnson, Alan R. Shuldiner
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:959-967
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibiti
Autor:
Mark Nelson, Christopher M. Reid, Sophia Xie, Joshua P. Lewis, Alan R. Shuldiner, Andrew Tonkin, Paul Lacaze, Rory Wolfe, John J McNeil, Galina Polekhina, Anne M. Murray, Moeen Riaz
Publikováno v:
Clin Pharmacol Ther
The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. However, association with atherothrombotic cardi
Autor:
Liewei Wang, Jill M. Pulley, Mark J. Ratain, Julie A. Johnson, Wolfgang Sadee, Rhonda M. Cooper-DeHoff, Teri E. Klein, Ruth E. Pakyz, Julie R. Field, Alan R. Shuldiner, Russ B. Altman, Mary V. Relling, Peter H. O'Donnell, Josh F. Peterson, Samuel K. Handelman, Peter J. Embi, Jasmine A. Luzum, Larisa H. Cavallari, Naveen L. Pereira, Cyrine E. Haidar, Kathleen Palmer, Michelle Whirl-Carrillo, Dan M. Roden, Kristin Weitzel, Robert R. Freimuth, Jonathan S. Schildcrout, Marc Beller, Amanda R. Elsey, Richard M. Weinshilboum
Publikováno v:
Clinical Pharmacology & Therapeutics. 102:502-510
Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (N
Autor:
Alan R. Shuldiner, Joshua P. Lewis
Publikováno v:
Clinical Pharmacology & Therapeutics. 101:323-325
While it is well established that genetic variation is a significant contributor to interindividual variability in clopidogrel efficacy, candidate gene and genome-wide approaches have failed to reproducibly identify genetic determinants of antiplatel
Autor:
Stuart A. Scott, Katrin Sangkuhl, Teri E. Klein, Jean-Sébastien Hulot, Alan R. Shuldiner, Julie A. Johnson, Marc S. Sabatine, Jessica L. Mega, Dan M. Roden, Charles M. Stein
Publikováno v:
Clinical Pharmacology & Therapeutics. 94:317-323
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-functio
Autor:
Dan M. Roden, K Hicks, Julie A. Johnson, Wolfgang Sadee, Robert R. Freimuth, Mary V. Relling, Teri E. Klein, Josh F. Peterson, Naveen L. Pereira, Alan R. Shuldiner
Publikováno v:
Clinical Pharmacology & Therapeutics. 94:207-210
The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Networ
Autor:
Larisa H. Cavallari, Alan R. Shuldiner, Joshua P. Lewis, Amber L. Beitelshees, Dan M. Roden, Julie A. Johnson
Publikováno v:
Clinical Pharmacology & Therapeutics. 90:519-531
Uncovering the causes of interpatient variability in drug response, and then using that information for the benefit of patients, is at the heart of clinical pharmacology. Although the term “pharmacogenetics” was coined in the 1950s, only in the p
Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions
Publikováno v:
Clinical Pharmacology & Therapeutics. 89:455-459
Clopidogrel is one of the most widely prescribed drugs in the United States, but it is associated with a great deal of interpatient variability in response (e.g., clopidogrel resistance).1 It is a prodrug that requires activation by cytochrome P450 e
Autor:
Kathleen M. Giacomini, Meghan J. Chenoweth, Alan R. Shuldiner, Rachel F. Tyndale, Mary V. Relling, Ron H.N. van Schaik, Munir Pirmohamed, Matthias Schwab, Sue Hill
Publikováno v:
CLINICAL PHARMACOLOGY & THERAPEUTICS
Clinical Pharmacology & Therapeutics, 107(1), 57-61. Wiley-Blackwell
Clin Pharmacol Ther
Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics, 107(1), 57-61. Wiley-Blackwell
Clin Pharmacol Ther
Clinical Pharmacology & Therapeutics